Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s ReproCell Biotech To Be First To Commercialize iPS Cells

This article was originally published in PharmAsia News

Executive Summary

ReproCell, a Japanese biotech start-up, is expected be the nation's first company to produce and market a human induced pluripotent stem cell product. The plan is to use iPS cells created at Kyoto University as the basis for a service to detect the side effects of drugs. The company already had been producing the cells using monkey embryonic stem cells. The market for such diagnoses are pharmaceutical firms that seekd to avoid costly side effects that interfere with clinical trials. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts